145 related articles for article (PubMed ID: 19048695)
1. Treatment of relapsed or refractory aggressive non-hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE.
Aurer I; Mitrović Z; Nemet D; Radman I; Sertić D; Serventi-Seiwerth R; Stern-Padovan R; Santek F; Nola M; Mrsić M; Labar B
J Chemother; 2008 Oct; 20(5):640-4. PubMed ID: 19048695
[TBL] [Abstract][Full Text] [Related]
2. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
3. Combination of ifosfamide, methotrexate, and etoposide (IMVP) as a salvage therapy for relapsed and refractory aggressive non-Hodgkin lymphoma: retrospective study.
Aurer I; Duraković N; Radman I; Nemet D; Zupancić-Salek S; Kovacević-Metelko J; Bogdanić V; Sertić D; Mrsić M; Mikulić M; Labar B
Croat Med J; 2002 Oct; 43(5):550-4. PubMed ID: 12402394
[TBL] [Abstract][Full Text] [Related]
4. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[TBL] [Abstract][Full Text] [Related]
6. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
[TBL] [Abstract][Full Text] [Related]
7. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
8. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
9. Treatment of refractory and relapsed non-Hodgkin's lymphoma with ifosfamide, methotrexate and etoposide.
Sangster G; Patton WN; Harris RI; Grieve RJ; Leyland MJ
Cancer Chemother Pharmacol; 1989; 23(4):263-5. PubMed ID: 2924382
[TBL] [Abstract][Full Text] [Related]
10. A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy.
Sawada M; Tsurumi H; Yamada T; Hara T; Fukuno K; Goto H; Shimizu M; Kasahara S; Yoshikawa T; Kanemura N; Oyama M; Takami T; Moriwaki H
Eur J Haematol; 2002 Jun; 68(6):354-61. PubMed ID: 12225393
[TBL] [Abstract][Full Text] [Related]
11. Toxicity and efficacy of ifosfamide, carboplatin and etoposide (modified ICE) as a salvage chemotherapy in Japanese patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Itoh K; Igarashi T; Ohtsu T; Wakita H; Watanabe Y; Fujii H; Minami H; Sasaki Y
Int J Hematol; 1998 Dec; 68(4):431-7. PubMed ID: 9885442
[TBL] [Abstract][Full Text] [Related]
12. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
Salar A; Martino R; Perea G; Ribera JM; López-Guillermo A; Guardia R; Escoda L; Altés A; Sierra J; Montserrat E
Haematologica; 2002 Oct; 87(10):1028-35. PubMed ID: 12368156
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma.
Moskowitz CH; Bertino JR; Glassman JR; Hedrick EE; Hunte S; Coady-Lyons N; Agus DB; Goy A; Jurcic J; Noy A; O'Brien J; Portlock CS; Straus DS; Childs B; Frank R; Yahalom J; Filippa D; Louie D; Nimer SD; Zelenetz AD
J Clin Oncol; 1999 Dec; 17(12):3776-85. PubMed ID: 10577849
[TBL] [Abstract][Full Text] [Related]
15. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
[TBL] [Abstract][Full Text] [Related]
16. A pilot study on the use of outpatient fractionated ifosfamide, carboplatin and etoposide (ICE) and pegfilgrastim as a salvage and mobilizing regimen for relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
George B; Benson W; Hertzberg MS
Bone Marrow Transplant; 2012 Jul; 47(7):1001-2. PubMed ID: 22002487
[No Abstract] [Full Text] [Related]
17. Risk-adapted therapy for relapsed and refractory lymphoma using ICE chemotherapy.
Moskowitz C
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S9-12. PubMed ID: 12042983
[TBL] [Abstract][Full Text] [Related]
18. Dose-intensive ifosfamide for the treatment of non-Hodgkin's lymphoma.
Vose JM
Semin Oncol; 1996 Jun; 23(3 Suppl 6):33-7. PubMed ID: 8677446
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
20. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
